PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL + human leukemia

Abstract excerpt

blast cells and drug-insensitive LSCs and confers a survival advantage in preclinical xenotransplant models. Thus, dual PP2A and BCR-ABL inhibition may be a valuable therapeutic strategy to synergistically target drug-insensitive LSCs that maintain minimal residual disease in patients.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer-related gene regulation
• Share to Chronic Lymphocytic Leukemia Research
• Share to Chronic Myeloid Leukemia Treatments